



US009492393B2

(12) **United States Patent**
McKenna et al.

(10) **Patent No.:** **US 9,492,393 B2**
(45) **Date of Patent:** ***Nov. 15, 2016**

(54) **TAMPER RESISTANT DOSAGE FORMS**

(71) Applicants: **Purdue Pharma L.P.**, Stamford, CT (US); **Purdue Pharmaceuticals L.P.**, Wilson, NC (US)

(72) Inventors: **William H. McKenna**, Yonkers, NY (US); **Richard O. Mannion**, Furlong, PA (US); **Edward P. O'Donnell**, Basking Ridge, NJ (US); **Haiyong H. Huang**, Princeton, NJ (US)

(73) Assignees: **PURDUE PHARMA L.P.**, Stamford, CT (US); **PURDUE PHARMACEUTICALS L.P.**, Wilson, NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/729,660**

(22) Filed: **Jun. 3, 2015**

(65) **Prior Publication Data**
US 2015/0265600 A1 Sep. 24, 2015

Related U.S. Application Data

(60) Continuation of application No. 14/515,924, filed on Oct. 16, 2014, now Pat. No. 9,084,816, which is a continuation of application No. 13/803,132, filed on Mar. 14, 2013, now abandoned, which is a division of application No. 11/844,872, filed on Aug. 24, 2007, now Pat. No. 8,894,987.

(60) Provisional application No. 60/840,244, filed on Aug. 25, 2006.

(51) **Int. Cl.**
A61K 31/485 (2006.01)
A61K 9/28 (2006.01)
A61K 47/10 (2006.01)
A61K 9/20 (2006.01)
A61K 9/16 (2006.01)
A61J 3/06 (2006.01)
A61K 9/00 (2006.01)
A61K 47/34 (2006.01)
A61K 9/24 (2006.01)
A61K 45/06 (2006.01)
A61J 3/10 (2006.01)
B29C 43/00 (2006.01)

(52) **U.S. Cl.**
CPC .. **A61K 9/28** (2013.01); **A61J 3/06** (2013.01); **A61J 3/10** (2013.01); **A61K 9/0002** (2013.01); **A61K 9/1641** (2013.01); **A61K 9/209** (2013.01); **A61K 9/2013** (2013.01); **A61K 9/2018** (2013.01); **A61K 9/2031** (2013.01); **A61K 9/2054** (2013.01); **A61K 9/2077** (2013.01); **A61K 9/2095** (2013.01); **A61K 9/2853** (2013.01); **A61K 9/2866** (2013.01);

A61K 9/2893 (2013.01); **A61K 31/485** (2013.01); **A61K 45/06** (2013.01); **A61K 47/10** (2013.01); **A61K 47/34** (2013.01); **B29C 43/003** (2013.01); **A61K 9/2072** (2013.01)

(58) **Field of Classification Search**
CPC .. A61K 31/485; A61K 9/2893; A61K 47/10; A61K 51/1258
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

636,438 A 11/1899 Lovejoy
1,468,805 A 9/1923 Freund
1,485,673 A 3/1924 Freund
2,772,270 A 11/1956 Weiss
3,096,248 A 7/1963 Rudzki
3,806,603 A 4/1974 Gaunt et al.
3,885,027 A 5/1975 Shaw et al.
3,941,865 A 3/1976 Miller et al.
3,966,747 A 6/1976 Monkovic et al.
3,980,766 A 9/1976 Shaw et al.
4,070,494 A 1/1978 Hoffmeister et al.
4,175,119 A 11/1979 Porter
4,404,183 A 9/1983 Kawata et al.
4,501,828 A 2/1985 Hadermann et al.
4,599,342 A 7/1986 LaHann
4,612,008 A 9/1986 Wong et al.
4,616,644 A 10/1986 Saferstein et al.
4,619,988 A 10/1986 Leung et al.
4,629,621 A 12/1986 Snipes
4,629,624 A 12/1986 Grouiller et al.
4,690,822 A 9/1987 Uemura et al.
4,713,243 A 12/1987 Schiraldi et al.
4,744,976 A 5/1988 Snipes et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 1110972 A1 10/1981
CA 2352874 A1 6/2000

(Continued)

OTHER PUBLICATIONS

Mai et al. (Materiaux et Constructions 1982. 15(2); pp. 99-106).*

(Continued)

Primary Examiner — Misook Yu

Assistant Examiner — Kausar Akhoun

(74) *Attorney, Agent, or Firm* — Troutman Sanders LLP

(57) **ABSTRACT**

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

30 Claims, 27 Drawing Sheets

(56)

References Cited

U.S. PATENT DOCUMENTS

4,764,378 A	8/1988	Keith et al.	6,723,340 B2	4/2004	Gusler et al.
4,765,989 A	8/1988	Wong et al.	6,733,783 B2	5/2004	Oshlack et al.
4,774,074 A	9/1988	Snipes	6,864,370 B1	3/2005	Lin et al.
4,783,337 A	11/1988	Wong et al.	6,919,373 B1	7/2005	Lam et al.
4,806,337 A	2/1989	Snipes et al.	6,930,129 B2	8/2005	Lam et al.
4,861,598 A	8/1989	Oshlack	7,129,248 B2	10/2006	Chapman et al.
RE33,093 E	10/1989	Schiraldi et al.	7,141,250 B2	11/2006	Oshlack et al.
4,892,778 A	1/1990	Theeuwes et al.	7,153,966 B2	12/2006	Casner et al.
4,960,814 A	10/1990	Wu et al.	7,157,103 B2	1/2007	Sackler
4,970,075 A	11/1990	Oshlack	7,201,920 B2	4/2007	Kumar et al.
5,004,601 A	4/1991	Snipes	7,399,488 B2	7/2008	Hirsh et al.
5,019,397 A	5/1991	Wong et al.	7,674,799 B2	3/2010	Chapman et al.
5,051,222 A	9/1991	Marten et al.	7,674,800 B2	3/2010	Chapman et al.
5,139,790 A	8/1992	Snipes	7,683,072 B2	3/2010	Chapman et al.
5,169,645 A	12/1992	Shukla et al.	7,776,314 B2	8/2010	Bartholomaeus et al.
5,200,197 A	4/1993	Wright et al.	7,842,307 B2	11/2010	Oshlack et al.
5,211,892 A	5/1993	Gueret	8,114,383 B2	2/2012	Bartholomaeus et al.
5,266,331 A	11/1993	Oshlack et al.	8,163,798 B2	4/2012	Gupta et al.
5,273,758 A	12/1993	Royce	8,309,060 B2	11/2012	Bartholomaeus et al.
5,273,760 A	12/1993	Oshlack et al.	8,337,888 B2	12/2012	Wright et al.
5,286,493 A	2/1994	Oshlack et al.	8,808,741 B2	8/2014	McKenna et al.
5,330,766 A	7/1994	Morella et al.	8,815,289 B2	8/2014	McKenna et al.
5,350,741 A	9/1994	Takada	8,821,929 B2	9/2014	McKenna et al.
5,356,467 A	10/1994	Oshlack et al.	8,834,925 B2	9/2014	McKenna et al.
5,378,474 A	1/1995	Morella et al.	8,846,086 B2	9/2014	McKenna et al.
5,393,528 A	2/1995	Staab	8,894,987 B2	11/2014	McKenna et al.
5,405,366 A	4/1995	Fox et al.	8,894,988 B2	11/2014	McKenna et al.
5,458,887 A	10/1995	Chen et al.	8,911,719 B2	12/2014	McKenna et al.
5,472,712 A	12/1995	Oshlack et al.	9,084,816 B2	7/2015	McKenna et al.
5,478,577 A	12/1995	Sackler et al.	2001/0031278 A1	10/2001	Oshlack et al.
5,508,042 A	4/1996	Oshlack et al.	2001/0036476 A1	11/2001	Oshlack et al.
5,549,912 A	8/1996	Oshlack et al.	2001/0038852 A1	11/2001	Kolter et al.
5,580,578 A	12/1996	Oshlack et al.	2002/0051820 A1	5/2002	Shell et al.
5,654,005 A	8/1997	Chen et al.	2002/0114838 A1	8/2002	Ayer et al.
5,656,295 A	8/1997	Oshlack et al.	2002/0187192 A1	12/2002	Joshi et al.
5,672,360 A	9/1997	Sackler et al.	2002/0192277 A1	12/2002	Oshlack et al.
5,695,781 A	12/1997	Zhang et al.	2003/0004177 A1	1/2003	Kao et al.
5,801,201 A	9/1998	Graudums et al.	2003/0015814 A1	1/2003	Krull et al.
5,849,240 A	12/1998	Miller et al.	2003/0044464 A1	3/2003	Ziegler et al.
5,866,161 A	2/1999	Childers et al.	2003/0064099 A1	4/2003	Oshlack et al.
5,866,164 A	2/1999	Kuczynski et al.	2003/0065002 A1	4/2003	Caruso et al.
5,886,164 A	3/1999	Bird et al.	2003/0068375 A1*	4/2003	Wright A61K 9/2013 424/468
5,914,131 A	6/1999	Merrill et al.	2003/0068392 A1	4/2003	Sackler
5,945,125 A	8/1999	Kim	2003/0069318 A1	4/2003	Dang et al.
5,948,787 A	9/1999	Merrill et al.	2003/0091630 A1	5/2003	Louie-Helm et al.
5,958,452 A	9/1999	Oshlack et al.	2003/0092724 A1	5/2003	Kao et al.
5,958,459 A	9/1999	Chasin et al.	2003/0104052 A1	6/2003	Berner et al.
5,968,551 A	10/1999	Oshlack et al.	2003/0104053 A1	6/2003	Gusler et al.
6,008,355 A	12/1999	Huang et al.	2003/0118641 A1	6/2003	Maloney et al.
6,009,690 A	1/2000	Rosenberg et al.	2003/0124185 A1	7/2003	Oshlack et al.
6,096,339 A	8/2000	Ayer et al.	2003/0129234 A1	7/2003	Baichwal et al.
6,117,453 A	9/2000	Seth et al.	2003/0133985 A1	7/2003	Louie-Helm et al.
6,177,567 B1	1/2001	Chiu et al.	2003/0152622 A1	8/2003	Louie-Helm et al.
6,228,863 B1	5/2001	Palermo et al.	2003/0161882 A1	8/2003	Waterman
6,238,697 B1	5/2001	Kumar et al.	2003/0203024 A1	10/2003	Sako et al.
6,245,357 B1	6/2001	Edgren et al.	2003/0224051 A1	12/2003	Fink et al.
6,251,430 B1	6/2001	Zhang et al.	2003/0229158 A1	12/2003	Chen et al.
6,261,599 B1	7/2001	Oshlack et al.	2004/0010000 A1	1/2004	Ayer et al.
6,262,266 B1	7/2001	Chiu et al.	2004/0011806 A1	1/2004	Luciano et al.
6,277,409 B1	8/2001	Luber et al.	2004/0024006 A1	2/2004	Simon
6,306,438 B1	10/2001	Oshlack et al.	2004/0047907 A1	3/2004	Oshlack et al.
6,309,668 B1	10/2001	Bastin et al.	2004/0110781 A1	6/2004	Harmon et al.
6,340,475 B2	1/2002	Shell et al.	2004/0126428 A1	7/2004	Hughes et al.
6,357,957 B1	3/2002	Champlin	2004/0137156 A1	7/2004	Lee et al.
6,375,957 B1	4/2002	Kaiko et al.	2004/0156899 A1	8/2004	Louie-Helm et al.
6,436,441 B1	8/2002	Sako et al.	2004/0170680 A1	9/2004	Oshlack et al.
6,461,644 B1	10/2002	Jackson et al.	2004/0185097 A1	9/2004	Kannan et al.
6,488,962 B1	12/2002	Berner et al.	2004/0185105 A1	9/2004	Berner et al.
6,488,963 B1	12/2002	McGinity et al.	2004/0213848 A1	10/2004	Li et al.
6,491,683 B1	12/2002	Dong et al.	2004/0241234 A1	12/2004	Vilkov
6,534,089 B1	3/2003	Ayer et al.	2005/0031546 A1*	2/2005	Bartholomaeus A61K 9/2031 424/10.1
6,547,997 B1	4/2003	Breitenbach et al.	2005/0106249 A1	5/2005	Hwang et al.
6,572,885 B2	6/2003	Oshlack et al.	2005/0112067 A1	5/2005	Kumar et al.
6,635,280 B2	10/2003	Shell et al.	2005/0127555 A1	6/2005	Gusik et al.
6,699,503 B1	3/2004	Sako et al.	2005/0152843 A1	7/2005	Bartholomaeus et al.
			2005/0222188 A1	10/2005	Chapman et al.
			2005/0236741 A1	10/2005	Arkenau et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2005/0266084 A1 12/2005 Li et al.
 2006/0002859 A1 1/2006 Arkenau et al.
 2006/0002860 A1 1/2006 Bartholomaus et al.
 2006/0173029 A1 8/2006 Chapman et al.
 2006/0188447 A1 8/2006 Arkenau-Maric et al.
 2006/0193914 A1 8/2006 Ashworth et al.
 2006/0240107 A1 10/2006 Lenaerts et al.
 2006/0240110 A1 10/2006 Kiick et al.
 2006/0251724 A1 11/2006 Farrell et al.
 2006/0269603 A1 11/2006 Brown Miller et al.
 2007/0003616 A1 1/2007 Arkenau-Maric et al.
 2007/0020335 A1 1/2007 Chen et al.
 2007/0048228 A1 3/2007 Arkenau-Maric et al.
 2007/0092573 A1 4/2007 Joshi et al.
 2007/0117826 A1 5/2007 Janjikel et al.
 2007/0117829 A1 5/2007 Chapman et al.
 2007/0117831 A1 5/2007 Chapman et al.
 2007/0183979 A1 8/2007 Arkenau-Maric et al.
 2007/0183980 A1 8/2007 Arkenau-Maric et al.
 2007/0196396 A1 8/2007 Pilgaonkar et al.
 2008/0175908 A1 7/2008 Liu et al.
 2008/0248113 A1 10/2008 Bartholomaus et al.
 2008/0274183 A1 11/2008 Cook
 2008/0317854 A1 12/2008 Arkenau et al.
 2009/0005408 A1 1/2009 Arkenau-Maric et al.
 2009/0022798 A1 1/2009 Rosenberg et al.
 2009/0081290 A1 3/2009 McKenna et al.
 2010/0168148 A1 7/2010 Wright et al.
 2011/0038930 A1 2/2011 Barnscheid et al.
 2013/0251796 A1 9/2013 McKenna et al.
 2013/0251797 A1 9/2013 McKenna et al.
 2013/0251800 A1 9/2013 McKenna et al.
 2013/0251801 A1 9/2013 McKenna et al.
 2013/0259938 A1 10/2013 McKenna et al.
 2014/0024669 A1 1/2014 McKenna et al.
 2014/0030327 A1 1/2014 McKenna et al.
 2015/0028512 A1 1/2015 McKenna et al.
 2015/0037411 A1 2/2015 McKenna et al.
 2015/0037412 A1 2/2015 McKenna et al.
 2015/0037413 A1 2/2015 McKenna et al.

FOREIGN PATENT DOCUMENTS

CA 2502965 A1 5/2004
 CA 2534925 A1 2/2005
 CA 2534932 A1 2/2005
 CA 2551231 A1 7/2005
 CA 2572491 A1 1/2006
 CH 689109 A5 10/1998
 CN 1130352 C 12/2003
 CN 1514721 A 7/2004
 DE 4309528 A1 9/1994
 DE 19753534 A1 6/1999
 DE 19800698 A1 7/1999
 DE 19822979 A1 12/1999
 DE 19855440 A1 6/2000
 DE 10036400 A1 6/2002
 DE 10227077 6/2002
 DE 69429710 T2 8/2002
 DE 10250083 A1 12/2003
 DE 10250084 A1 5/2004
 DE 10336400 A1 3/2005
 EP 0008131 A1 2/1980
 EP 0111144 A1 6/1984
 EP 0177893 A2 4/1986
 EP 0216453 A2 4/1987
 EP 0226061 A2 6/1987
 EP 0228417 A1 7/1987
 EP 0232877 A2 8/1987
 EP 0277289 A1 8/1988
 EP 0293066 A2 11/1988
 EP 0328775 A1 8/1989
 EP 0583726 A2 2/1994
 EP 0598606 A1 5/1994
 EP 0647448 A1 4/1995

EP 0661045 A1 7/1995
 EP 0682945 A2 11/1995
 EP 0693475 A1 1/1996
 EP 0696598 A1 2/1996
 EP 0780369 A1 6/1997
 EP 0820698 A1 1/1998
 EP 0889045 A1 1/1999
 EP 0974343 A1 1/2000
 EP 0980894 A1 2/2000
 EP 0998271 A1 5/2000
 EP 1250045 A2 10/2002
 EP 1293127 A2 3/2003
 EP 1658055 A1 5/2006
 EP 1859789 A1 11/2007
 EP 1897545 A1 3/2008
 EP 2070538 A1 6/2009
 EP 2080514 A1 7/2009
 EP 2082742 A1 7/2009
 EP 2292229 A1 3/2011
 EP 2292230 A1 3/2011
 EP 2311459 A1 4/2011
 EP 2343071 A1 7/2011
 EP 2388475 A1 11/2011
 EP 2399579 A1 12/2011
 EP 2399580 A1 12/2011
 GB 2450691 A 1/2009
 WO WO-9003776 A1 4/1990
 WO WO-9107950 A1 6/1991
 WO WO-9306723 A1 4/1993
 WO WO-9310758 A1 6/1993
 WO WO-9311749 A1 6/1993
 WO WO-9406414 A1 3/1994
 WO WO-9408567 A1 4/1994
 WO WO-9514460 A1 6/1995
 WO WO-9520947 A1 8/1995
 WO WO-9522319 A1 8/1995
 WO WO-9530422 A1 11/1995
 WO WO-9600066 A1 1/1996
 WO WO-9608253 A1 3/1996
 WO WO-9614058 A1 5/1996
 WO WO-9632097 A1 10/1996
 WO WO-9733566 A2 9/1997
 WO WO-9737689 A2 10/1997
 WO WO-9749384 A1 12/1997
 WO WO-9749385 A1 12/1997
 WO WO-9820073 A2 5/1998
 WO WO-9844911 A1 10/1998
 WO WO-9856354 A2 12/1998
 WO WO-9856359 A2 12/1998
 WO WO-9920255 A1 4/1999
 WO WO-9932119 A1 7/1999
 WO WO-9932120 A1 7/1999
 WO WO-9944591 A1 9/1999
 WO WO-0009639 A2 2/2000
 WO WO-0032166 A2 6/2000
 WO WO-0033835 A1 6/2000
 WO WO-0115667 A1 3/2001
 WO WO-0145644 A2 6/2001
 WO WO-0226928 A1 4/2002
 WO WO-02087512 A2 11/2002
 WO WO-03013476 A1 2/2003
 WO WO-03013479 A1 2/2003
 WO WO-03015531 A2 2/2003
 WO WO-03024429 A1 3/2003
 WO WO-03024430 A1 3/2003
 WO WO-03026624 A1 4/2003
 WO WO-03028698 A2 4/2003
 WO WO-030286200 A1 4/2003
 WO WO-03035029 A1 5/2003
 WO WO-03035053 A1 5/2003
 WO WO-03035054 A1 5/2003
 WO WO-03035177 A2 5/2003
 WO WO-03053417 A2 7/2003
 WO WO-03072086 A1 9/2003
 WO WO-03094812 A1 11/2003
 WO WO-03105808 A1 12/2003
 WO WO-2004016618 A1 2/2004
 WO WO-2004026262 A2 4/2004
 WO WO-2004026263 A2 4/2004

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	WO-2004037230	A1	5/2004
WO	WO-2004037259	A1	5/2004
WO	WO-2004037260	A1	5/2004
WO	WO-2004093819	A2	11/2004
WO	2005/000310	A1	1/2005
WO	WO-2005016303	A2	2/2005
WO	WO-2005016313	A1	2/2005
WO	WO-2005016314	A1	2/2005
WO	WO-2005041968	A2	5/2005
WO	WO-2005063214	A1	7/2005
WO	WO-2005079760	A1	9/2005
WO	WO-2005097801	A1	10/2005
WO	WO-2005102286	A1	11/2005
WO	WO-2006002883	A1	1/2006
WO	WO-2006002884	A1	1/2006
WO	WO-2006002886	A1	1/2006
WO	0679550	A2	8/2006
WO	WO-2006082097	A1	8/2006
WO	WO-2006082099	A1	8/2006
WO	WO-2006084211	A2	8/2006
WO	WO-2007008752	A2	1/2007
WO	WO-2007048233	A1	5/2007
WO	WO-2007053698	A2	5/2007
WO	WO-2008086804	A2	7/2008
WO	WO-2009114648	A1	9/2009

OTHER PUBLICATIONS

- AlKhatib et al. (AAPS PharmSciTech, 2010, 11(1); pp. 253-266).*
- Mpofu et al. (Journal of Colloid and Interface Science, 2004, 271; pp. 145-156).*
- Remington, 20th Edition, 2003, "Oral Solid Dosage Forms"
- Remington, 20th Edition, 2003, "Sustained and Controlled-Release Drug Delivery Systems"
- Gissinger et al. A comparative evaluation of the properties of some tablet disintegrants, Drug Development and Industrial Pharmacy 6(5): 511-536, 1980.
- JB. Ashworth, et al., "Effect of Tablet mechanical Stability on Drug Preference and Relative Street Value of Oxycodone Controlled-Release (CR) Tablets in Experienced Oxycodone CR Abusers" (Abstract) Presented at the 69th Annual Scientific Meeting of the College on Problems of Drug Dependence (Quebec City, Canada, Jun. 16, 2007).
- J. Bartholomaeus, et al., "A New Technology to Increase the Mechanical Stability of Matrix Tablets to Prevent Abuse by Crushing or Chewing" (Abstract) Presented at the Drug Formulations and Abuse Liability Conference "Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions" (North Bethesda, Maryland, Apr. 19-20, 2005), pp. 12-13.
- V.K. Thoma et al., "Bestimmung der In-vitro-Freigabe von schwach basischen Wirkstoffen aus Retardarzneiformen," Pharm. Ind. 51, Nr. 3 (1989).
- S. Janicki et al., "Slow-Release Microballs: Method of Preparation," Acta Pharm. Technol. 33(3) 154-155 (1987).
- R. Mank et al., "Darstellung wirkstoffhaltiger Extrusionsformlinge auf der Basis von Thermoplasten," Pharmazie 45 (1990), H. 8; pp. 592-593.
- R. Mank et al., "Darstellung wirkstoffhaltiger Extrusionsformlinge auf der Basis von Thermoplasten," Pharmazie 44 (1989) H. 11; pp. 773-776.
- P. Shivanand et al., "Factors Affecting Release of KCl from Melt Extruded Polyethylene Disks," Pharmaceutical Research, Official Journal of the American Association of Pharmaceutical Scientists; Oct. 1991, vol. 8, No. 10.
- L. Yang et al., "Characterization of Compressibility and Compatibility of Poly(ethylene oxide) Polymers for Modified Release Application by Compaction Simulator," Journal of Pharmaceutical Sciences, vol. 85, No. 10, Oct. 1996.
- F. Zhang et al., "Properties of Sustained-Release Tablets Prepared by Hot-Melt Extrusion," Pharmaceutical Development and Technology, 4(2), 241-250 (1999) pp. 241-250.
- A. Apicella et al., "Poly(ethylene oxide) (PEO) and different molecular weight PEO blends monolithic devices for drug release," Biomaterials 1993, vol. 14, No. 2, pp. 83-90.
- M.M. Crowley et al., "Stability of polyethylene oxide in matrix tablets prepared by hot-melt extrusion," Biomaterials 23 (2002) 4241-4248.
- M. Efentakis et al., "Evaluation of High Molecular Weight Poly(Oxyethylene) (Polyox) Polymer: Studies of Flow Properties and Release Rates of Furosemide and Captopril from Controlled-Release Hard Gelatin Capsules," Pharmaceutical Development and Technology, 5(3), 339-346 (2000).
- N. Follonier et al., "Various ways of modulating the release of diltiazem hydrochloride from hot-melt extruded sustained release pellets prepared using polymeric materials," Journal of Controlled Release 36 (1995) 243-250.
- N.B. Graham, "Poly(Ethylene Glycol) Gels and Drug Delivery," Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, Chapter 17, 1992.
- C. D. Hanning et al., "The Morphine Hydrogel Suppository," British Journal of Anaesthesia, 1988, 61, 221-227.
- Kim et al., "Preparation and Evaluation of Eudragit Gels V. Rectal Gel Preparations for Sustained Release and Avoidance of First-Pass Metabolism of Lidocaine," Chem. Pharm. Bull. 40(10) 2800-2804 (1992).
- Cherng-Ju Kim, "Drug Release from Compressed Hydrophilic POLYOX-WSR Tablets," Journal of Pharmaceutical Sciences, vol. 84, No. 3, Mar. 1995.
- S.L. Madorsky et al., "Thermal Degradation of Polyethylene Oxide and Polypropylene Oxide," Journal of Polymer Science, vol. XXXVI, pp. 183-194 (1959).
- A. Moroni et al., "Application of Poly(Oxyethylene) Homopolymers in Sustained Release Solid Formulations," Drug Development and Industrial Pharmacy, 21(12), 1411-1428 (1995).
- N. Ohnishi et al., "Effect of the Molecular Weight of Polyethylene Glycol on the Bioavailability of Indomethacin Sustained-Release Suppositories Prepared with Solid Dispersions," Chem. Pharm. Bull., 35 (8) 3511-3515 (1987).
- T. Ozeki et al., "Control of medicine release from solid dispersion composed of the poly(ethylene oxide)-carboxyvinylpolymer interpolymer complex by varying molecular weight of poly(ethylene oxide)," Journal of Controlled Release 58 (1999) 87-95.
- Pharmaceutical Research, Official Journal of the American Association of Pharmaceutical Scientists, Sep. 1989 (Supplement), vol. 6, No. 9, 6.S-98.
- Pharmaceutical Research, Official Journal of the American Association of Pharmaceutical Scientists, Oct. 1991 (Supplement), Vol. 8, No. 10, 8.S-192.
- W. Prapaitrakul et al., "Release of Chlorpheniramine Maleate from Fatty Acid Ester Matrix Disks Prepared by Melt-extrusion," J. Pharm. Pharmacol. 1991, 43: 377-381.
- J. Scheirs et al., "Characterizing the solid-state thermal oxidation of poly(ethylene oxide) powder," Polymer, 1991, vol. 32, No. 11.
- O.L. Sprockel et al., "Permeability of Cellulose Polymers: Water Vapour Transmission Rates," J. Pharm. Pharmacol. 1990, 42: 152-157.
- J.L. Stringer et al., "Diffusion of small molecular weight drugs in radiation-crosslinked poly(ethylene oxide) hydrogels," Journal of Controlled Release 42 (1996) 195-202.
- E. G. Rippie et al., "Regulation of Dissolution Rate by Pellet Geometry," Journal of Pharmaceutical Sciences, Vol. 58, No. 4, Apr. 1969, pp. 428-431.
- Remington's Pharmaceutical Sciences 17th ed., Mack Publishing Co., (1985) 1418.
- M.S. Mesiha et al., "A Screening Study of Lubricants in Wet Powder Masses Suitable for Extrusion-Spheronization," Drug Development and Industrial Pharmacy, 19(8), 943-959 (1993).
- N. Follonier et al., "Evaluation of Hot-Melt Extrusion as a New Technique for the Production of Polymer-Based Pellets for Sustained Release Capsules Containing High Loadings of Freely Soluble Drugs," Drug Development and Industrial Pharmacy, 20(8), 1323-1339 (1994).
- "2.9.8. Resistance to Crushing of Tablets," Pharmaceutical Technical Procedures, European Pharmacopoeia, p. 135 (1997).

(56)

References Cited

OTHER PUBLICATIONS

- Bauer et al., Coated Pharmaceutical Dosage Forms: Fundamentals, Manufacturing Techniques, Biopharmaceutical Aspects, Test Methods and Raw Materials, Scientific Publishers Stuttgart 1998, CRC Press, 8 pp.
- Commonwealth of Australia, In the matter of Australian Patent Application No. 2002305559 in the name of Endo Pharmaceuticals, Inc. and Opposition thereto by Mundipharma Pty Limited, ampm A0111098466v3 206030879 1.10., pp. 1-4, 2008.
- Coppens et al., "Hypromellose, Ethylcellulose, and Polyethylene Oxide Use in Hot Melt Extrusion," *Pharmaceutical Technology*, 5 pp. (2005/2006).
- Huang, Hugh, Poster and Abstract on extruded POLYOX tablets presented at the poster session of 2000 AAPS Annual Meeting, 4 pp.
- Maggi et al., "Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (PEOs) for the controlled release of a water-soluble drug. Dimensionality study," *Biomaterials*, vol. 23, pp. 1113-1119 (2002).
- Proeschel et al., "Task-dependence of Activity/Bite-force Relations and its Impact on Estimation of Chewing Force from EMG," *J Dent Res*, vol. 81, No. 7, pp. 464-468 (2002).
- Schroeder et al., "Granulierung hydrophober Wirkstoffe im Planetwalzenextruder" (Summary in English), *Wissenschaft und Technik, Pharm. Ind.*, vol. 65, No. 4, 367-372 (2003).
- "Oral Solid Dosage Forms," Remington's Pharmaceutical Sciences, 18th edition, Chapter 89, pp. 1633-1665 (1990).
- Chiao et al., "Sustained-Release Drug Delivery Systems," Remington: The Science and Practice of Pharmacy, Chapter 94, Alfonso R. Gennaro, Ed., pp. 1660-1675 (1995).
- EP1014941: Opposition brief filed by opponent Grunenthal dated Dec. 23, 2009 (includes English-language translation) (24 pages).
- EP1658054: Affidavit by Inventor of EP1658054, Prof. Johannes Bartholomaeus, dated Oct. 7, 2009, with English translation (28 pages).
- EP1658054: Annex to Third party observation—Test Report by Professor McGinity dated Jan. 26, 2009 (4 pages).
- EP1658054: English translation of Patentee's response dated Jan. 15, 2009 (Reference C7) (8 pages).
- EP1658054: Opposition brief filed on Mar. 27, 2008 (15 pages).
- EP1658054: Patentee's Response to Opposition dated Jan. 15, 2009 (12 pages).
- EP1658054: Third party observation dated Feb. 2, 2009 (4 pages).
- EP1658054: Third party observation dated Mar. 27, 2009 (3 pages).
- EP1658054: Wolfgang, Ritschel, Die Tablette: Handbuch der Entwicklung, Herstellung und Qualitätssicherung (extract), with English translation (2002) (5 pages).
- EP1658055: Annex to Third Party Observation—Test Report by Prof. McGinity dated Jan. 26, 2009 (4 pages).
- EP1658055: Berger et al., Water-Soluble Resins, pp. 169-201 (1962) (34 pages).
- EP1658055: Ethylene Oxide Polymers, Union Carbide Corporation, Technical Booklet (reprinted from Encyclopedia of Polymer Science and Technology, vol. 6, pp. 103-145 (1967)).
- EP1658055: European Pharmacopoeia, 3rd Ed., chapter 2.9.8, 3 pages (1997).
- EP1658055: Excerpt from Purdue Laboratory notebook (calibrated Instron test results) (4 pages)—Mar. 12, 2008.
- EP1658055: Experimental Report—Breaking strength tests on calibrated Instron tester dated Mar. 12, 2008 (4 pages).
- EP1658055: Experimental Report—Breaking strength tests on uncalibrated Instron tester dated Dec. 6, 2007 (10 pages).
- EP1658055: IP Search, Summary of prior art search for EP1658055 provided by Swiss Intellectual Property Office dated Dec. 3, 2007 (117 pages).
- EP1658055: Opposition brief filed on Dec. 14, 2007 (14 pages).
- EP1658055: Patentee's Response to Opposition dated Oct. 31, 2008, with English translation (23 pages).
- EP1658055: Third Party Observation dated Feb. 2, 2009 (4 pages).
- EP1658055: Third Party Observation dated Mar. 27, 2009 (3 pages).
- EP1897545: Communicated dated Dec. 20, 2007 from the European Patent Office containing the European Search Report (6 pages).
- EP1897545: Response to Office Communication dated May 21, 2008 (15 pages).
- EP2070538: Annex1 of the Report: Photos from First Hydration Rate (9 pages)—Mar. 5, 2010.
- EP2070538: Communication dated Jun. 25, 2009 from the European Patent Office (4 pages).
- EP2070538: Communication dated May 18, 2009 from the European Patent Office including the European Search Report (3 pages).
- EP2070538: Response to Office Communicated dated Mar. 5, 2010 (23 pages).
- EP2080514: Communication dated Jun. 15, 2009 from the European Patent Office containing the European Search Report (3 pages).
- EP2080514: Office Action from EPO dated Jul. 14, 2009 (4 pages).
- EP2080514: Response to Office Communicated dated Mar. 19, 2010 (14 pages).
- EP2082742: Communication dated Jul. 9, 2009 from the European Patent Office (4 pages).
- EP2082742: Communication dated Jun. 15, 2009 from the European Patent Office containing the European Search Report (3 pages).
- EP2082742: Response to Office Communication dated Mar. 19, 2010 (21 pages).
- Falbe et al. (Eds.), "Rompp Chemie Lexikon," with English translation, 9 pages (1992).
- Andrx Lab Paragraph IV Letter, Feb. 7, 2011. [Confidential—Filed Under Seal].
- Watson Paragraph IV Letter, Feb. 7, 2011. [Confidential—Filed Under Seal].
- Teva Paragraph IV Letter, Feb. 9, 2011. [Confidential—Filed Under Seal].
- Actavis Paragraph IV Letter, Feb. 15, 2011. [Confidential—Filed Under Seal].
- Purdue v. Impax Paragraph IV Letter*, Feb. 23, 2011. [Confidential—Filed Under Seal].
- Ranbaxy Paragraph IV Letter, Feb. 24, 2011. [Confidential—Filed Under Seal].
- Ranbaxy Paragraph IV Letter, Mar. 23, 2010. [Confidential—Filed Under Seal].
- Mylan Paragraph IV Letter, Apr. 1, 2010. [Confidential—Filed Under Seal].
- Actavis Paragraph IV Letter, Apr. 8, 2010. [Confidential—Filed Under Seal].
- Ranbaxy Paragraph IV Letter, Apr. 8, 2010. [Confidential—Filed Under Seal].
- Mylan Paragraph IV Letter (U.S. Pat. No. 7,683,072), Apr. 9, 2010. [Confidential—Filed Under Seal].
- Mylan Paragraph IV Letter (U.S. Pat. No. 7,674,799 and U.S. Pat. No. 7,674,800), Apr. 9, 2010. [Confidential—Filed Under Seal].
- Varam, Inc. Paragraph IV Letter, Jun. 28, 2010. [Confidential—Filed Under Seal].
- Ranbaxy Paragraph IV Letter (NDA No. 02-2272), Aug. 25, 2011. [Confidential—Filed Under Seal].
- Purdue Paragraph IV Letter (Amneal Pharmaceuticals), Sep. 28, 2011. [Confidential—Filed Under Seal].
- Sandoz Paragraph IV Letter, May 23, 2011 [Confidential—Filed Under Seal].
- Podczek et al., "Investigations into the tensile failure of doubly-convex cylindrical tablets under diametral loading using finite element methodology," *International Journal of Pharmaceutics* 454 (2013) 412-424.
- Wikipedia—Newton (unit) (2014).
- Purdue v. Teva*, Trial Decision (Case 04-MD-01603-SHS 568) (# 149 Jan. 14, 2014).
- Report: *Cured v. Heat-Compressed PEO Tablets* (Mar. 2010); submitted in EP 2 070 538 (Application No. 09156832.9) and other EP and foreign applications.
- Choi et al., "Development of a directly compressible poly(ethylene oxide) matrix for the sustained-release of dihydrocodeine bitartrate" *Drug Dev and Ind. Pharm*, 2003, 29(10), 1045-1052.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.